Bonmassar A, Riccardi C, Rivosecchi-Merletti P, Goldin A, Bonmassar E
Int J Cancer. 1980 Dec 15;26(6):819-29. doi: 10.1002/ijc.2910260617.
Sequential treatment of mice with non-lethal doses of 5(3,3'-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC) and cyclophosphamide (Cy) was found to produce long-term inhibition of endogenous cell proliferation in the spleen and profound impairment of classical allograft responses, similar to that detectable in lethally irradiated mice. Studies were carried out with drug-treated (i.e. treated with DTIC + Cy) conventional or nude mice inoculated with lymphoma cells homozygous for the H-2b or H-2d haplotype. Transplantation resistance in various tumour-host combinations was studied in terms of survival times after tumor challenge or lymphoma cell proliferation in spleen and liver, measured by the uptake of DNA precursor 125I-labelled 5-iodo-2'-deoxyuridine ([125I]dUrd). The results of in vivo transplantation immunity tests or in vitro tests of generation of cytotoxic lymphocytes confirmed that classical T-dependent allograft responses were abrogated by drug treatment of H-2-incompatible hosts. However, localized resistance against lymphoma graft, mainly at spleen level, was found in drug-treated hybrid mice, or conventional and "nude" allogeneic recipients, as judged by [123I]dUrd uptake inhibition. Resistance presumably regulated, at least in part by the Hh (hemopoietic histocompatibility) system, was abrogated by pretreatment with carrageenan, an antimacrophage agent. In addition, treatment with DTIC + Cy did not abrogate NK activity of mice when the in vitro cytotoxicity test was conducted 5 h after Cy administration, i.e. at the time used for tumor challenge in vivo. It was concluded that selected immunological functions (i.e., antilymphoma natural resistance insensitive to DTIC + Cy, called drug-resistant inhibition of tumors, DRIT) possibly of non-T origin, similar to those detectable in lethally-irradiated mice, can be retained by hosts subjected to high doses of certain anti-tumor agents.
研究发现,用非致死剂量的5(3,3'-二甲基-1-三氮烯基)-咪唑-4-甲酰胺(DTIC)和环磷酰胺(Cy)对小鼠进行序贯治疗,可长期抑制脾脏内源性细胞增殖,并严重损害经典的同种异体移植反应,这与在致死性照射小鼠中可检测到的情况相似。对用药物处理(即用DTIC + Cy处理)的常规或裸鼠进行了研究,这些小鼠接种了H-2b或H-2d单倍型纯合的淋巴瘤细胞。通过肿瘤攻击后的存活时间或脾脏和肝脏中淋巴瘤细胞的增殖情况(通过DNA前体125I标记的5-碘-2'-脱氧尿苷([125I]dUrd)的摄取来测量),研究了各种肿瘤-宿主组合中的移植抗性。体内移植免疫试验或细胞毒性淋巴细胞生成的体外试验结果证实,对H-2不相容宿主进行药物治疗可消除经典的T细胞依赖性同种异体移植反应。然而,通过[123I]dUrd摄取抑制判断,在药物处理的杂种小鼠、常规和“裸”同种异体受体中,发现了对淋巴瘤移植的局部抗性,主要在脾脏水平。这种抗性可能至少部分由Hh(造血组织相容性)系统调节,用抗巨噬细胞剂角叉菜胶预处理可消除这种抗性。此外,当在Cy给药后5小时(即体内用于肿瘤攻击的时间)进行体外细胞毒性试验时,用DTIC + Cy处理并未消除小鼠的NK活性。得出的结论是,经过高剂量某些抗肿瘤药物处理的宿主可能保留了某些可能非T细胞起源的选定免疫功能(即对DTIC + Cy不敏感的抗淋巴瘤天然抗性,称为肿瘤的耐药性抑制,DRIT),这与在致死性照射小鼠中可检测到的情况相似。